IDEAYA Biosciences, Inc. Common Stock IDYA
$38.87
+2.48%
at last close
Analyst Consensus
- Consensus Rating
- Buy (14 Buy · 1 Hold · 0 Sell)
- Average Price Target
- $52.86
- Implied Upside
- +36.0%
- Price Target Range
- $35.00 – $79.00
- Analysts (12 mo)
- 15
Recent Analyst Actions
| Date | Firm | Action | Rating | Price Target |
|---|---|---|---|---|
| 2026-08-05 | Truist SecuritiesGregory Renza |
Maintains | Buy | $63 → $59 |
| 2026-08-05 | WedbushRobert Driscoll |
Maintains | Outperform | $58 → $60 |
| 2026-07-07 | RBC CapitalLeonid Timashev |
Maintains | Outperform | $53 → $48 |
| 2026-07-07 | Truist SecuritiesGregory Renza |
Maintains | Buy | $65 → $63 |
| 2026-06-12 | WedbushRobert Driscoll |
Reiterates | Outperform | $58 |
| 2026-06-02 | WedbushRobert Driscoll |
Reiterates | Outperform | $58 |
| 2026-05-07 | MizuhoGraig Suvannavejh |
Maintains | Outperform | $52 → $50 |
| 2026-04-14 | Goldman SachsCorinne Jenkins |
Maintains | Neutral | $31 → $35 |
| 2026-04-14 | Wells FargoEva Fortea Verdejo |
Maintains | Overweight | $44 → $48 |
| 2026-04-14 | RBC CapitalLeonid Timashev |
Maintains | Outperform | $49 → $53 |
| 2026-04-14 | WedbushRobert Driscoll |
Maintains | Outperform | $52 → $58 |
| 2026-04-14 | GuggenheimPaul Jeng |
Maintains | Buy | $50 → $54 |
| 2026-03-31 | WedbushRobert Driscoll |
Reiterates | Outperform | $52 |
| 2026-02-19 | CitigroupYigal Nochomovitz |
Maintains | Buy | $64 → $65 |
| 2026-02-18 | RBC CapitalLeonid Timashev |
Reiterates | Outperform | $49 |
| 2026-02-18 | GuggenheimPaul Jeng |
Reiterates | Buy | $50 |
| 2026-02-18 | WedbushRobert Driscoll |
Maintains | Outperform | $49 → $52 |
| 2026-01-21 | RBC CapitalLeonid Timashev |
Maintains | Outperform | $41 → $45 |
| 2026-01-07 | UBSMichael Yee |
Assumes | Buy | $50 |
| 2026-01-06 | Truist SecuritiesGregory Renza |
Maintains | Buy | $59 → $60 |
| 2025-11-24 | Truist SecuritiesGregory Renza |
Initiates coverage on | Buy | $59 |
| 2025-11-11 | MizuhoGraig Suvannavejh |
Maintains | Outperform | $44 → $46 |
| 2025-10-23 | JP MorganAnupam Rama |
Maintains | Overweight | $74 → $79 |
| 2025-10-21 | Goldman SachsCorinne Jenkins |
Maintains | Neutral | $27 → $30 |
| 2025-10-21 | RBC CapitalLeonid Timashev |
Maintains | Outperform | $38 → $41 |
| 2025-10-21 | BTIGJustin Zelin |
Reiterates | Buy | $62 |
| 2025-09-18 | GuggenheimPaul Jeng |
Initiates coverage on | Buy | $50 |
| 2025-09-12 | MizuhoGraig Suvannavejh |
Maintains | Outperform | $43 → $44 |
| 2025-09-09 | RBC CapitalLeonid Timashev |
Maintains | Outperform | $36 → $38 |
| 2025-09-09 | Cantor FitzgeraldLi Watsek |
Reiterates | Overweight | — |
Ratings and price targets reflect each firm's most recent published action. Consensus combines the latest call from every covering firm over the past 12 months; price targets are typically 12-month horizons.
Key Stats
- Last Close
- $38.87
- Market Cap
- $3.66 billion
- 52-Week Range
- $21.33 – $40.58
- Average Volume
- 725K shs
Data is delayed and provided for informational purposes only. Not investment advice. See our disclaimer.